Anterix (ATEX) Cash & Equivalents (2016 - 2025)
Anterix filings provide 13 years of Cash & Equivalents readings, the most recent being $29.5 million for Q4 2025.
- On a quarterly basis, Cash & Equivalents rose 2.56% to $29.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.5 million, a 2.56% increase, with the full-year FY2025 number at $47.4 million, down 21.8% from a year prior.
- Cash & Equivalents hit $29.5 million in Q4 2025 for Anterix, down from $39.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $127.8 million in Q4 2021 to a low of $28.8 million in Q4 2024.
- Median Cash & Equivalents over the past 5 years was $54.6 million (2022), compared with a mean of $64.9 million.
- Biggest five-year swings in Cash & Equivalents: tumbled 66.42% in 2023 and later soared 78.12% in 2024.
- Anterix's Cash & Equivalents stood at $127.8 million in 2021, then tumbled by 54.99% to $57.5 million in 2022, then increased by 7.86% to $62.0 million in 2023, then plummeted by 53.58% to $28.8 million in 2024, then grew by 2.56% to $29.5 million in 2025.
- The last three reported values for Cash & Equivalents were $29.5 million (Q4 2025), $39.1 million (Q3 2025), and $41.4 million (Q2 2025) per Business Quant data.